US Broker Ratings

AnaptysBio, Inc. (ANAB) Investor Outlook: Exploring a 36.95% Potential Upside in the Biotech Sector

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company based in San Diego, is making waves in the healthcare sector. With a robust focus on immunology therapeutics, AnaptysBio presents a compelling..

Taysha Gene Therapies (TSHA) Stock Analysis: Biotech Innovator with 97.90% Upside Potential

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is positioned at the frontier of the biotechnology sector, offering investors a compelling opportunity in the realm of gene therapies for central nervous system..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring a 152.61% Potential Upside in Gene Editing Revolution

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is making waves in the biotech sector with its groundbreaking focus on genome editing treatments, positioning itself as a critical player in the evolving landscape..

Neuropace, Inc. (NPCE) Stock Analysis: Unveiling a 22.3% Potential Upside in the Medical Device Sector

For investors seeking opportunities within the healthcare sector, particularly in the realm of medical devices, Neuropace, Inc. (NASDAQ: NPCE) presents an intriguing prospect. With a focus on treating drug-resistant focal..

Evolus, Inc. (EOLS) Stock Analysis: Aiming High with Over 150% Potential Upside

Evolus, Inc. (NASDAQ: EOLS) is capturing the attention of investors with its significant growth potential, evidenced by a staggering 157.66% potential upside. As a key player in the healthcare sector,..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Biotech Gem with 143% Potential Upside

Niagen Bioscience, Inc. (NAGE), a prominent player in the biotechnology industry, has captured the attention of investors with its remarkable potential upside of 143.08%. Operating within the healthcare sector, Niagen..

Zymeworks Inc. (ZYME) Stock Analysis: A Promising Biotech Play with a 34.62% Upside Potential

For investors eager to capitalize on the burgeoning biotechnology sector, Zymeworks Inc. (NASDAQ: ZYME) presents an intriguing opportunity. With a market capitalization of $2 billion, this clinical-stage biotech company is..

OrthoPediatrics Corp. (KIDS) Investor Outlook: Analysts Forecast 37% Upside Potential

OrthoPediatrics Corp. (NASDAQ: KIDS), a leader in the pediatric orthopedic medical devices sector, presents a compelling opportunity for investors seeking exposure to the healthcare industry. With a focus on designing..

Dianthus Therapeutics, Inc. (DNTH): Investor Outlook on a Biotech with 51% Upside Potential

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a pioneering entity in the biotechnology sector, has been capturing investor attention with its ambitious approach to treating severe autoimmune and inflammatory diseases. A closer..

CureVac N.V. (CVAC) Investor Outlook: Assessing a 26.20% Potential Upside in the Innovative mRNA Space

CureVac N.V. (NASDAQ: CVAC), a prominent player in the biotechnology sector, presents a compelling case for investors intrigued by the transformative potential of messenger RNA (mRNA) technologies. Headquartered in Tübingen,..

Akso Health Group (AHG) Stock Analysis: Unpacking the 415.8% Revenue Growth in China’s Booming Healthcare Sector

Akso Health Group (AHG), a prominent player in China’s medical distribution industry, is capturing headlines with its remarkable 415.8% revenue growth. As a healthcare company operating a multifaceted e-commerce platform,..

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: A 94.3% Upside Potential Amid Biotech Innovations

Individual investors eyeing the biotechnology sector may find Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) an intriguing prospect given its innovative cancer therapies and promising market performance indicators. Operating in the healthcare..

Delcath Systems, Inc. (DCTH) Investor Outlook: A 124% Potential Upside in the Expanding Oncology Market

Delcath Systems, Inc. (NASDAQ: DCTH) has recently captured the attention of investors with its notable potential upside of 124.62%, according to analyst ratings. As an interventional oncology company, Delcath is..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 148% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN), a clinical-stage biopharmaceutical company, is gaining attention in the biotechnology sector for its promising pipeline of cancer therapies. Headquartered in Boulder, Colorado, Enliven Therapeutics is..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Uncovering a 144.90% Potential Upside in the Biotech Arena

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a promising player in the biotechnology sector, has caught the attention of individual investors with its substantial market cap of $708.05 million and a remarkable..

iRadimed Corporation (IRMD) Stock Analysis: A Healthcare Leader with a Robust 15.7% Revenue Growth

iRadimed Corporation (NASDAQ: IRMD) operates at the intersection of healthcare and technology, focusing on innovative MRI-compatible medical devices. With its headquarters in Winter Springs, Florida, the company has carved out..

Avadel Pharmaceuticals plc (AVDL) Stock Report: Understanding the 54.9% Revenue Growth Amidst Market Challenges

Avadel Pharmaceuticals plc (NASDAQ: AVDL), an Ireland-based specialty drug manufacturer, has captured investor attention with its robust revenue growth of 54.9% over the past year. As a player in the..

STAAR Surgical Company (STAA) Stock Analysis: Navigating Growth with a 10.58% Upside Potential

STAAR Surgical Company (NASDAQ: STAA), a prominent player in the healthcare sector specializing in medical instruments and supplies, is making waves with its innovative solutions in the world of ophthalmology...

Beta Bionics, Inc. (BBNX) Stock Analysis: Growth Potential and Analyst Consensus Point to an 11.15% Upside

Beta Bionics, Inc. (NASDAQ: BBNX), a promising player in the healthcare sector, particularly within the medical devices industry, is making waves with its innovative solutions aimed at improving the lives..

Weave Communications, Inc. (WEAV) Stock Analysis: Potential 47% Upside in the Health Information Services Sector

Weave Communications, Inc. (NYSE: WEAV) presents a compelling opportunity for investors eyeing the health information services industry. As a key player in providing customer experience and payments software for small..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds